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ABSTRACT
Attention deficit hyperactivity disorder (ADHD) is a common
developmental disorder characterized by impulsivity, inattention, and
hyperactivity. In rodents, neonatal 6-OHDA lesions is an established model of
ADHD because it produces symptoms of hyperactivity and cognitive deficits that
improve following psychostimulant treatment. Recently, early alcohol exposure
in rodents has also been suggested as a model of ADHD due to the high
prevalence of ADHD in children exposed prenatally to alcohol. However, children
exposed to prenatal alcohol differ in symptoms from children with idiopathic
ADHD, suggesting that ADHD caused by prenatal alcohol exposure may be a
special subtype of ADHD or a completely different disorder. The aim of the
present study was to compare the 6-OHDA lesion model with the effects of early
alcohol exposure on hyperactivity, psychostimulant response, and passive
avoidance learning in preweanling rats. It was hypothesized that alcohol
exposure and the combined effects of a 6-OHDA lesion and exposure to alcohol
would result in increased locomotor hyperactivity and poorer performance on the
passive avoidance task. A total of 1,053 male and female Sprague-Dawley rats
were lesioned with 6-OHDA or placed in a lesion control group on postnatal day
(PD 3). Beginning on PD 4, rats were exposed to alcohol (0, 0.3, or 3 g/kg) for six
consecutive days or were unhandled. On PD 19, rats were habituated to a
locomotor chamber for 60 min. On the following day (PD 20), the rats were
injected with amphetamine (1 mg/kg), methylphenidate (2.5 mg/kg) or saline and
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locomotor activity was measured for 60 min. On PD 23, a separate group of rats
were trained on a passive avoidance task and retention was tested for three
consecutive days. Our results demonstrated that exposure to a low dose of
alcohol can cause an increase in the locomotor activity of female rats, while
exposure to a high dose of alcohol can disrupt memory. In addition, our results
indicated that 6-OHDA lesions and alcohol exposure do not have an additive
effect. In summary, these data suggest neonatal alcohol can cause a dose
dependent increase in ADHD-like symptoms.
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CHAPTER ONE:
ADHD
Attention Deficit Hyperactivity Disorder (ADHD) is a highly prevalent
disorder affecting children regardless of socio-economic background or ethnicity.
ADHD was initially known as “hyperkinetic disorder of childhood” and is found
predominantly in males (Curatolo, D'Agati, & Moavero, 2010; Kiely, 2015). A
recent systematic review and meta-analysis estimated that approximately 7% of
children worldwide, under the age of 18, meet the diagnostic criteria for ADHD
(Thomas, Sanders, Doust, Beller, & Glasziou, 2015).
The three core symptoms of ADHD, inattention, hyperactivity, and
impulsivity, correspond with the clinical presentations of the disorder: Inattentive,
hyperactive-impulsive, and combined type (Baumeister, Henderson, Pow, &
Advokat, 2012). Symptomology of ADHD can vary across settings, such as in the
home, school, and workplace (Kiely, 2015; Russell, 2011). In the inattentive
presentation, the individual has difficulty staying focused, is disorganized, has
difficulty following instructions or conversations and is forgetful. The symptoms of
hyperactive-impulsive presentation include fidgeting, impulsivity, and disruption
of others. In the combined presentation the reported symptoms are a blend of
inattentive and hyperactive-impulsive (American Psychiatric Association, 2013).
ADHD is defined as a disruptive neurobehavioral disorder, because it is
associated with academic struggles, socialization issues, and increased criminal

1

behavior (Punja et al., 2016; Watts, 2018). The symptoms of ADHD are
excessive, pervasive, and persistent in that the behaviors are extreme, show up
in multiple settings, and can be long-term. ADHD is often comorbid with other
disorders, such as oppositional defiant disorder, major depressive disorder, and
anxiety (Sharma & Couture, 2014; Watts, 2018).
Currently, there is no screening test available to detect ADHD nor is there
a cure; thus, only treatment is available for individuals with ADHD. Treatments for
ADHD include behavioral therapy, dietary restrictions, and pharmacological
intervention (Shier, Reichenbacher, Ghuman, & Ghuman, 2013).
Psychostimulant compounds, such as methylphenidate and amphetamine, are
recommended as the first-line of treatment for ADHD (Chung, Tchaconas,
Meryash, & Adesman, 2016; Shier et al., 2013). For the 30% of ADHD patients
not suitable for psychostimulants there are alternative options, such as
atomoxetine and α-2 agonists (Curatolo et al., 2010; Kiely, 2005). Stimulant and
non-stimulant treatments are effective; however, a number of concerns involving
long-term effects are still unanswered.

Neurobiology of ADHD
The etiology and pathophysiology of ADHD are not yet completely
understood, but a number of structural, functional, neurochemical, and genetic
abnormalities in the brains of individuals with ADHD have been identified.
Magnetic resonance imaging (MRI) studies have reported smaller anatomical
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areas and volumes in patients with ADHD (Castellanos et al., 2002). There is a
reduction in total brain size in children with ADHD that persists into adolescence
and their brain volumes are decreased by 3% when compared to controls
(Castellanos et al., 2002; Tripp & Wickens, 2009). Cortical thinning is a robust
neuroanatomical marker for ADHD in childhood and adolescence (Narr et al.,
2009; Shaw et al., 2006; Tripp & Wickens, 2009) and the rate at which cortical
thinning occurs is correlated with the severity of hyperactivity and impulsivity
(Shaw et al., 2011).
A review of neuroimaging studies involving individuals with ADHD
indicates that the prefrontal cortex (PFC), caudate, and cerebellum are the
primary brain regions showing reduced volumes (Sharma & Couture, 2014).
These reductions may be of importance, because these regions are involved in
cognitive processing, attention, emotion, and behavior regulation (Sharma &
Couture, 2014). In addition, neuroimaging studies on children with ADHD found
reductions of the amygdala, thalamus, hippocampus, cerebellar vermis, splenium
of the corpus callosum, as well as abnormal asymmetry of the caudate nucleus
and the pallidum (Kasparek, Theiner, & Filova, 2015; Tripp & Wickens, 2009).
Asymmetry of the caudate is related to severity of attention deficits (Schrimsher,
Billingsley, Jackson, & Moore, 2002).
A recent meta-analysis of functional magnetic resonance imaging (fMRI)
studies showed consistent differences between individuals with and without
ADHD in two distinct domains: inhibition and attention. Abnormalities of inhibition
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were related to the right hemispheric fronto-basal ganglia networks, including the
inferior frontal cortex, supplementary motor area, and anterior cingulate cortex
(Hart, Radua, Nakao, Mataix-Cols, & Rubia, 2013). In the attention domain, the
areas exhibiting reduced activity were the dorsolateral prefrontal cortex (DLPFC)
and cerebellar areas (Hart, et al., 2013; Kasparek et al., 2015). Furthermore, Hart
et al. (2013) reported a different pattern of brain dysfunction during inhibition
tasks in children and adults with ADHD. Specifically, hypoactivation of the
supplementary motor area and basal ganglia was present in children, while
hypoactivation of the inferior frontal cortex and thalamus was detected in adults.
Neurochemical theories of ADHD have been around since at least 1970
(Baumeister et al., 2012). Dysfunction of monoamine systems is suspected,
because the fronto-subcortical circuits associated with ADHD are rich in
catecholamines, and the most effective drugs used to treat ADHD are
psychostimulants that block dopamine (DA) and norepinephrine (NE)
transporters (Curatolo et al., 2010; Sagvolden, Russell, Aase, Johansen, &
Farshbaf, 2005). Furthermore, functional activation studies on individuals with
ADHD show that long-term treatment with stimulant medication is associated with
normalization of caudate activity (Hart et al., 2013).
ADHD has a complex etiology, and multiple genetic factors are thought to
play an important role. Numerous studies have found a strong familial genetic
contribution, with the heritability rate estimated at 76% (Curatolo et al., 2010;
Shier et al., 2013; Tripp & Wickens, 2009). Twin studies have also demonstrated
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high heritability of approximately 0.80 (Kieling, Goncalves, Tannock, &
Castellanos, 2008). No single gene yet discovered plays a major role, but gene
associations have been found (Shier et al., 2013; Tripp & Wickens, 2009). The
genes that may be involved are those coding for D4 (DRD4) and D5 receptors
(DRD5), the DA transporter (DAT1), the norepinephrine transporter (NET1),
synaptosomal-associated protein 25 (SNAP-25), the serotonin transporter
(5HTT), and the serotonin 1B receptor (HTR1B) (Russell, 2011; Sharma &
Couture, 2014; Tripp & Wickens, 2009). In rodent brains, the SRY gene is highly
expressed in areas that contain dense populations of dopaminergic neurons,
which have been implicated in the pathophysiology of ADHD (Kiely, 2015).
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CHAPTER TWO:
ADHD PHARMACOTHERAPIES
ADHD can be treated effectively with pharmacological agents, behavioral
therapies, and a combination of both. Psychostimulants are the most widely used
treatment for ADHD and have been used for over 50 years. Psychostimulant
treatment is associated with improved academic achievement in school and
improved quality of life (Shier et al., 2013). Currently, an estimated 2.8 million
children in the United States take psychostimulants for ADHD (Baumeister et al.,
2012; Shier et al., 2013).
The two most commonly prescribed psychostimulants for the treatment of
ADHD are methylphenidate (MPH) and amphetamine (AMP). These
psychostimulants work by increasing synaptic levels of NE and DA, are available
in immediate or extended release forms, and are efficacious for short- and longterm use (Punja et al., 2016; Shier et al., 2013). Common adverse effects of
stimulant medications include loss of appetite, stomachache, insomnia, and
headaches (Shier et al., 2013). Unusual side-effects include tics, irritability, and
increased heart rate and blood pressure. A majority of long-term follow-up
studies on stimulant medications did not find an increased risk for substance use,
abuse, or dependence in adulthood (Shier et al., 2013).
Amphetamine increases the availability of NE and DA in the synaptic cleft
by stimulating release and inhibiting re-uptake and metabolism (Shier et al.,
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2013). A common formulation of AMP is Adderall (Sharma & Couture, 2014). In
contrast, MPH works by blocking the DAT and NET transporters (Curatolo et al.,
2010). MPH increases extracellular levels of DA in the prefrontal cortex, nucleus
accumbens, and caudate nucleus (Kasparek et al., 2015). Some of the brand
names for MPH include Ritalin, Concerta, and Methylin (Sharma & Couture,
2014). Although their clinical effects are qualitatively similar, MPH has milder side
effects than AMP. MPH has a half-life of about 2 hours versus AMP’s half-life of 7
to 30 hours (Baumeister et al., 2012). Furthermore, MPH is less likely to produce
psychosis and other side effects (Baumeister et al., 2012).
Because of their efficacy, psychostimulants are considered first-line
agents for the treatment of ADHD (Shier et al., 2013). However, non-stimulant
medications are an important second option for treating ADHD. Typically, these
compounds are only used after the first-line agents have exhibited a poor
response or cannot be used (Sharma & Couture, 2014; Shier et al., 2013). Nonstimulants possess inferior efficacy compared to psychostimulants, but their side
effects are generally milder (Shier et al., 2013). Importantly, non-stimulants do
not have the same abuse potential as stimulants. The second-line medications
for the treatment of ADHD include atomoxetine, bupropion, α-2 agonists, and
tricyclic antidepressants (Sharma & Couture, 2014; Shier et al., 2013). Since
most of these second-line medications are seldom prescribed there is inadequate
empirical information regarding efficacy and safety of higher doses (Shier et al.,
2013).
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Atomoxetine (ATX) is a potent selective norepinephrine reuptake inhibitor
that works by enhancing DA and NE transmission in cortical and subcortical
areas, but has limited actions in the striatum (Curatolo et al., 2010; Sharma &
Couture, 2014; Shier et al., 2013). ATX promotes attention and executive
functioning in ADHD individuals (Curatolo et al., 2010). ATX is the most favorable
of the non-stimulants because of its safety and efficacy (Himpel, Banaschewski,
Heise, & Rothenberger, 2005). ATX reduces tics and anxiety, thus it can serve as
a good alternative for ADHD individuals with these comorbidities (Sharma &
Couture, 2014).
Bupropion has a similar mechanism of action as both psychostimulants
and ATX, as bupropion inhibits the reuptake of DA and NE (Sharma & Couture,
2014). Bupropion is available in immediate and extended release form, but due
to its short half-life a twice daily administration is recommended (Sharma &
Couture, 2014). This pharmacological agent improves the ADHD symptom of
hyperactivity (Shier et al., 2013). FDA warnings of increased risk of suicidal
thoughts and behaviors are applicable to bupropion, since it is classified as an
antidepressant (Waxmonsky, 2005).
The immediate release α-2 agonists, guanfacine and clonidine, were
initially used off-label, until the FDA approved their use for the treatment of
ADHD in an extended release form (Sharma & Couture, 2014). These α-2
agonists stimulate presynaptic and postsynaptic α2 receptors resulting in
improved cognitive functioning in individuals with ADHD (Sharma & Couture,
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2014). Guanfacine, a selective α-2 agonist, strengthens the functional
connectivity of prefrontal cortex networks, resulting in improved working memory
(Curatolo et al., 2010). Clonidine, a nonspecific α-2 agonist, is more effective at
reducing symptoms of hyperactivity and impulsivity than symptoms of
inattentiveness (Waxmonsky, 2005). A common side-effect of clonidine is
sedation, which limits its daytime use (Waxmonsky, 2005). Unlike the previously
mentioned pharmacological agents, gradual withdrawal from α-2 agonists is
suggested to prevent potential risks associated with their actions as
antihypertensive agents (Shier et al., 2013).
The least preferred non-stimulant treatment for ADHD are the tricyclic
antidepressants (TCAs), because they have a wide range of negative sideeffects and drug interactions (Pliszka, 2003; Sharma & Couture, 2014). Until
concerns surfaced involving sudden death, TCAs were the primary second-line
treatments for ADHD (Pliszka, 2003). TCAs, like imipramine, are effective for
treating hyperactivity, but are only used when stimulants or alternative agents
prove ineffective (Himpel et al., 2005). TCAs may also be a reasonable
alternative for ADHD individuals who experience tics (Pliszka, 2003). Gradual
tapering off from these non-stimulants is recommended, due to the potential of
side-effects (Waxmonsky, 2005).
A fairly new, but promising, stimulant is modafinil, which was initially
approved for the treatment of narcolepsy (Shier et al., 2013; Waxmonsky, 2005).
The mechanism of action of this drug is not yet fully understood, but it is known
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to affect DA, NE and histamine (Shier et al., 2013). Modafinil has been used offlabel to treat ADHD symptoms and has been found to be effective in a few
studies (Biederman & Pliszka, 2008). The common side-effects of modafinil are
mild, including insomnia, headaches, and decreased appetite (Shier et al., 2013;
Waxmonsky, 2005).

10

CHAPTER THREE:
RODENT MODELS OF ADHD
Animal models have proven useful for understanding the cause of human
disorders and in developing treatments. To be useful, these models must
possess face validity, construct validity, or predictive validity (Russell, 2011).
Face validity refers to the animal model being able to mimic the fundamental
symptoms of the human disorder. Construct validity refers to the model having
similar etiology and underlying pathophysiological mechanisms. Lastly, models
that have predictive validity should display symptom to the same treatments
given to the clinical population, provide insight into the underlying mechanisms of
the disorder, as well as predict biological and behavioral aspects of the disorder
that are yet to be observed in clinical evaluations (Russell, 2011). In short, animal
models that are similar in terms of etiology, biochemistry, symptomatology, and
treatment are the most useful (Sagvolden et al., 2005).
The most thoroughly studied animal model of ADHD is the spontaneously
hypertensive rat (SHR) bred from the Wistar Kyoto control rat strain (WKY)
(Russell, 2011; Sagvolden et al., 2005). SHRs exhibit poor performance in visual
discrimination tasks that require sustained attention, they display impulsivity
during the extinction phase of an operant task, and hyperactivity is evident by
their increased response rates in free operant tasks and increased locomotor
activity in an open field (Russell, 2011; Sagvolden et al., 2005; Stanford &
Tannock, 2011). Similar to the neuropathology of children with ADHD, SHR rats
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have reduced brain volumes in the prefrontal cortex, occipital cortex, and
hippocampus. Moreover, there are fewer neurons in these brain areas when
compared to controls rats (Russell, 2011; Sagvolden et al., 2005). Dysfunction of
the DA and NE neurotransmitter systems are observed in this model (Sagvolden
et al., 2005). The SHR model has predictive validity, because medications used
to treat ADHD, such as MPH, AMP, and guanfacine improve behavioral deficits
(Stanford & Tannock, 2011). Even though this model displays numerous
behavioral characteristics similar to those observed in humans with ADHD, the
usefulness of the model has been criticized by a confounding factor of
hypertension, however hypertension does not develop until adulthood (Russell,
2011; Sagvolden et al., 2005).
A transgenic rodent model of ADHD, the DAT knock-out (DAT-KO) mouse
model, is also extensively studied. While the genetic basis of ADHD is not fully
understood, neurobiological evidence on the etiology of ADHD provides insight
into plausible genes that are involved. This rodent model is used to study the
absence of the gene that codes for DAT-1, which is responsible for synaptic DA
uptake (Sagvolden et al., 2005). The DAT-KO model provides useful information
on the neurobiological consequences of reduced midbrain DAT (Russell, 2011).
DAT-KO mice exhibit impulsivity and impairments on learning and memory tasks
(Stanford & Tannock, 2011; Sagvolden et al., 2005). DAT-KO mice are three to
five times more hyperactive than controls, possibly due to elevated extracellular
DA levels within the striatum (Sagvolden et al., 2005; Stanford & Tannock, 2011).
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Psychostimulants (e.g., MPH and AMP) attenuate hyperactivity in DAT-KO mice,
but extracellular DA concentrations are unchanged (Gainetdinov, Caron, &
Lombroso, 2001). These results suggest that non-dopaminergic systems are
involved in the modulation of locomotor activity in the DAT-KO mice model. While
a selective NE transporter inhibitor, nisoxetine, has no effect on the hyperactivity
of DAT-KO mice, the selective serotonin reuptake transporter (SERT) inhibitor,
fluoxetine, does reduce hyperactivity in this ADHD model (Gainetdinov et al.,
2001; Stanford & Tannock, 2011). DAT-KO mice provide convincing evidence
that the hyperactivity induced by elevated DA levels can be reduced by drugs
that activate the serotonergic system (Gainetdinov et al., 2001).
Environmentally-induced models of ADHD involve the application of an
exogenous manipulation, such as a toxin or trauma, to induce ADHD-like
phenotypes. In neonatal rats, anoxia causes permanent neurochemical
abnormalities in monoamine systems, along with hyperactivity and spatial
memory impairment (Puumala et al., 1996; Russell, 2011; Sagvolden et al.,
2005). Furthermore, amphetamine attenuated hyperactivity in the anoxia model,
thus supporting its use as an animal model of ADHD (Kostrzewa et al., 2008).
ADHD resulting from anoxia lacks construct validity and, hence, has not gained
popularity for the study of ADHD.
One of the most commonly-utilized ADHD models is the neonatal 6hydroxydopamine (6-OHDA) rat model. Administering an intracranial injection of
6-OHDA in neonatal rats causes selective and permanent DA depletion (Stanford
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& Tannock, 2011). This selective chemical lesion model has a phenotypic
resemblance to ADHD, because rats express hyperactivity and inattention, but
not impulsivity (Russell, 2011; Sagvolden et al., 2005; Stanford & Tannock,
2011). Neonatal 6-OHDA lesioned rats also display impaired learning in spatial
discrimination tasks (Russell, 2011). The neonatal 6-OHDA-lesioned rat has face
and predictive validity (Sagvolden et al., 2005; Stanford & Tannock, 2011). This
model has permitted the evaluation and prediction of the efficacy of new ADHD
therapies (Caballero et al., 2011). For example, both AMP and MPH reduce the
hyperactivity of neonatal 6-OHDA lesioned rats. Findings from these studies
suggest that the therapeutic effects of AMP and MPH may not be mediated
through the DA system, but rather through NE and SE transmission (Stanford &
Tannock, 2011; Russell, 2011).
A comparatively new pharmacological model of ADHD involves prenatal
alcohol exposure (PAE). In humans, PAE has been linked to impairments in
learning and memory, with ADHD being a common diagnosis (Marquardt &
Brigman, 2016; Patten, Fontaine & Christie, 2014; Rojas-Mayorquin et al., 2016).
Although prenatal alcohol treatment is not the typical method for modeling
ADHD, it is still representative because it has face and predictive validity
(Kostrzewa et al., 2008). The PAE model has face validity because rats exhibit
impulsivity, hyperactivity, and cognitive deficits, such as delays in learning and
memory, that are comparable to humans with ADHD (Atalar, Uzbay & Karakaş,
2016; Kostrzewa et al., 2008; Russell, 2011). PAE rats demonstrate reduced cell
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numbers in layers II and V of the medial prefrontal cortex and cerebellar cortex,
which likely results in the learning deficits. PAE rats also have neurochemical
deficits involving catecholamine, indolamine, and amino acid neurotransmitters,
similar to those observed in ADHD (Atalar et al., 2016; Rojas-Mayorquin et al.,
2016). The PAE model has predictive validity because the psychostimulant MPH
normalizes VTA DA neuron activity (Choong & Shen, 2004). In all, this animal
model mimics the behavioral, neuroanatomical, and
neuropsychopharmacological aspects of ADHD, thus making it a promising
model.
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CHAPTER FOUR:
ALCOHOL
Ethanol is the alcohol found in commonly consumed alcoholic beverages.
When ingested, alcohol acts as a central nervous system (CNS) depressant
(Roberto & Varodayan, 2017). Excessive alcohol use can result in a wide range
of behavioral and health problems, such as cardiovascular diseases, liver
cirrhosis, cancer, depression, and motor vehicle accidents (Liang & Olsen, 2014;
Tan et al., 2015). The consumption of alcohol in excess is the third leading cause
of preventable death in the United States, as reported by the Centers for Disease
Control and Prevention (CDC) (Liang & Olsen, 2014). An estimated 18 million
Americans over the age of 18 suffer from alcohol use disorders (AUD), creating a
substantial public health problem (Liang & Olsen, 2014; Roberto & Varodayan,
2017).

Alcohol Pharmacology
The pharmacodynamics of alcohol are complex, due to the various
neurotransmitter systems involved (Koob, 2004). Some of the systems known to
be affected by alcohol consumption include serotonin, GABA, and glutamate.
There is well-established evidence that alcohol alters 5-HT function with the most
consistent finding being potentiation of 5-HT3 receptor function (Banerjee, 2014;
Lovinger, 1999). Alcohol acts pre-synaptically at the GABA neuron to increase
GABA release and acts post-synaptically to enhance GABA receptor action
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(Banerjee, 2014; Koob, 2004). Alcohol increases GABA receptor action by
allowing more CI- to enter at the GABAA receptor, this results in inhibitory
postsynaptic potential (Davies, 2003; Koob, 2004). Alcohol also inhibits
glutamate activity in the brain. This decrease in glutamate transmission is
thought to be mediated via NMDA receptors (Banerjee, 2014; Koob, 2004).
Most of the alcohol consumed is metabolized in the liver (Zakhari, 2006).
The most common pathway involves alcohol dehydrogenase (ADH). ADH
metabolizes alcohol to acetaldehyde, which in turn, is converted to acetic acid in
the presence of aldehyde dehydrogenase (ALDH). Acetic acid is then oxidated to
carbon dioxide and water (Eberhart & Parnell, 2016; Zakhari, 2006). Although
ADH mediates the majority of the biotransformation of alcohol to acetaldehyde,
cytochrome P450 2E1 (CYP2E1) and catalase can also metabolize alcohol
(Eberhart & Parnell, 2016; Zakhari, 2006).

Prenatal Alcohol Exposure
The consumption of alcohol by pregnant women is particularly
problematic. A nationwide telephone survey by the Behavioral Risk Factor
Surveillance System (BRFSS) revealed that among women alcohol use is at
53.6% (Tan et al., 2015). The same poll indicated that the prevalence of alcohol
use by pregnant women was 10.2% (Tan et al., 2015). Interestingly, pregnant
women aged 35-44 and those with college degrees reported a higher rate of
alcohol use than other age groups and less educated women (Tan et al., 2015).
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Prenatal alcohol exposure (PAE) occurs when a woman drinks alcohol
while pregnant. The teratogenic effects of maternal ingestion of alcohol during
pregnancy has been observed in both human and animal populations (Cronise et
al., 2001). Numerous developmental, cognitive, and behavioral problems,
ranging from mild to severe, can occur from PAE (Gupta et al., 2016; Hausknecht
et al., 2005). The first disorder recognized to result from prenatal alcohol use was
fetal alcohol syndrome (FAS). This syndrome is characterized by facial
abnormalities, growth deficits, both prenatally and postnatally, as well as CNS
dysfunction (Thomas, Warren, & Hewitt, 2010). Because PAE produces such a
wide range of effects, and not all cases meet the diagnostic criteria for FAS,
there is now the umbrella term of fetal alcohol spectrum disorder (FASD) in
addition to FAS (Thomas et al., 2010).

FASD encompasses the broad range of impairments that can occur from
in utero alcohol exposure, such as deficits in intellectual performance, executive
function, learning and memory, language, sensory function, motor function,
behavior, and secondary disabilities including depression and anxiety (Hellemans
et al., 2010; Mattson et al., 2011; Schneider, Moore, & Adkins, 2011; Wetherill et
al., 2018). FASD includes partial FAS, which describes some but not all signs
and symptoms of FAS. FASD also includes alcohol-related birth defects (ARBD),
this being PAE-induced physical abnormalities. Lastly, FASD also includes
alcohol-related neurodevelopmental disorder (ARND), which incorporates
alcohol-induced impairments of growth and development of the CNS as well as
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cognitive and behavioral problems without facial or growth deformities (Thomas
et al., 2010). A recent meta-analysis of FASD reported a prevalence rate of 33.5
per 1,000 births in the United States (Wetherill et al., 2018). Because of the
lifelong consequences of PAE, it is considered to be a major social and economic
burden (Wetherill et al., 2018).

Rodent models are ideal for studying the effects of alcohol on
development, because rodent studies examining PAE show similar effects to
those observed in humans. In an MRI study, the brain images of mice and
humans exposed to comparable amounts of prenatal correspond well with each
other. For example, mice given a moderate dose of alcohol showed thinning of
the corpus collosum, similar to a child with partial FAS, while mice exposed to a
large dose of alcohol exhibited a severe reduction of the corpus collosum and
damage to the hippocampal commissure (O’Leary-Moore et al., 2011). Rodent
studies assessing the effects of PAE have also demonstrated impairments in
behavioral and cognitive function, including learning and memory deficits,
hyperactivity, hyper-responsivity to stressors, as well as deficits in both response
inhibition and the appropriate use of environmental cues, which are similar to
those observed in children with FASD (Cronise et al., 2001; Hellemans et al.,
2010; Schneider et al., 2011).

In humans and animals, a number of risk factors influence the
teratogenicity of alcohol and the probability of fetal alcohol-related effects. These
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risk factors are exposure pattern, dose, stress, environmental influences and
certain genetic variants (Schneider et al., 2011; Sulik, 2014). Due to the delicate
process of neurogenesis, the timing of alcohol exposure in relation to the
developing neural system can profoundly affect neuronal outcomes (Schneider et
al., 2011). FASD research conducted in rodents has determined that the first and
third trimesters are the most vulnerable periods for alcohol-induced
neuroteratogenesis (Dursun et al., 2006; Schneider et al. 2011; Sulik, 2014).
Environmental factors that may interact with and exacerbate the effects of
alcohol exposure include exposure to other drugs, maternal nutrition, and
obstetric complications (Russell, 2011).
The gene-alcohol interactions underlying FASD are not yet well
understood. Genes from the alcohol dehydrogenase (ADH) family have been
investigated for a potential genetic link with FASD. Investigations of human gene
alcohol interactions have focused on the major alcohol metabolizing enzyme,
ADH1 (Eberhart & Parnell, 2016; Gupta et al., 2016). This family has 3 loci:
ADH1A, ADH1B, and ADH1C. Data from these investigations have produced
contradictory results as to whether the ADH1B*3 allele works as a protective
mechanism or induces susceptibility to FASD. The ADH1B*3 allele clears alcohol
rapidly suggesting a protective mechanism (Neumark et al., 2004). Additionally,
maternal genotypes with at least one ADH1B*3 allele correlated with a lower rate
of FASD (Gupta et al., 2016). In contrast, mothers with an ADH1B*1/ADH1B*3
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genotype have a greater chance of bearing children with FASD (Eberhart &
Parnell, 2016).
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CHAPTER FIVE:
GABA & GLUTAMATE
The amino acid -aminobutyric acid (GABA) is an important
neurotransmitter in the regulation of brain neuronal activity. GABA is one of the
earliest expressed neurotransmitters during ontogeny. It is detectable during the
embryonic stage and is present throughout the lifespan (Wang & Kriegstein,
2009). During embryonic development, GABA acts in an excitatory manner and
is implicated in neurogenesis (Allen et al., 2015; Wang & Kriegstein, 2009; Wu &
Sun, 2015). As the brain matures, GABA’s function switches from excitatory to
inhibitory (Allen et al., 2015; Wang & Kriegstein, 2009; Wu & Sun, 2015). GABA
and the excitatory neurotransmitter glutamate modulate the inhibitory-excitatory
balance necessary for proper brain function (Allen et al., 2015; Wu & Sun, 2015).
The imbalance of either GABA or glutamate can result in several pathologies,
including anxiety, depression, and schizophrenia (Allen et al., 2015; Wu & Sun,
2015).

GABA Synthesis, Release, and Catabolism
GABA is synthesized from glutamate via the enzyme glutamate
decarboxylase (GAD) (Wong, Bottiglieri & Snead, 2003). Once synthesized,
GABA is packaged into vesicles by vesicular GABA transporters (VGAT). When
the presynaptic neuron is depolarized it releases GABA into the synaptic cleft via
calcium dependent exocytosis (Wong et al., 2003; Wu & Sun, 2015). After
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release, GABA is removed from the cleft by GABA transporter proteins (GATs)
(Wu & Sun, 2015). GABA is metabolized by GABA transaminase to form succinic
semialdehyde (Wong et al., 2003). Succinic semialdehyde is then oxidized by
succinic semialdehyde dehydrogenase to succinate (Ravasz et al., 2017).

Glutamate Synthesis, Release, and Catabolism
Glutamate is a non-essential amino acid that serves as the major
excitatory neurotransmitter of the nervous system (Yelamanchi et al., 2016).
Within the presynaptic terminal, glutamate is synthesized from glutamine by
glutaminase (Hertz, 2011; Meyer & Quenzer, 2005; Yelamanchi et al., 2016).
Three different vesicular glutamate transporters move glutamate into synaptic
vesicles: VGLUT1, VGLUT2, and VGLUT3 (Zhou & Danbolt, 2014). Synaptic
release of glutamate occurs from nerve terminals by exocytosis in synaptic
vesicles (Zhou & Danbolt, 2014). Once released into the synaptic cleft, glutamate
activity can be terminated by uptake via high affinity transporters located in glial
cells and presynaptic terminals (Meyer & Quenzer, 2005). The glutamate taken
back into glial cells is converted into glutamine via glutamine synthetase and
reintroduced in the glutamine–glutamate cycle (Hertz, 2013; Meyer & Quenzer,
2005).

GABA Receptors
GABA stimulates two receptor subtypes GABAA and GABAB, both of which
contribute to the long-term inhibition of synaptic transmission (Banerjee, 2014).
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These receptors differ from one another in structure, function, and sequence.
GABAA has 13 ionotropic receptor subunits (α1-6, β1-3, γ1-3 and δ) and is
considered a fast-synaptic inhibitory receptor (Allen et al., 2015; Sigel &
Steinmann, 2012; Wong et al., 2003; Wu & Sun, 2015). When activated, GABAA
receptors allow CI- into the cell membrane (Allen et al., 2015). High densities of
GABAA receptors are found in the limbic system, retina, and spinal cord (Allen et
al., 2015). In contrast, GABAB receptors are metabotropic (Sigel & Steinmann,
2012; Wong et al., 2003; Wu & Sun, 2015). GABAB receptors have two subtypes:
GABAB1 and GABAB2 (Wu & Sun, 2015). GABAB receptors are slow synaptic
inhibitors that regulate K+ and Ca2+ channels via a G-protein mediated
mechanism (Allen et al., 2015; Koob, 2004; Wong et al., 2003; Wu & Sun, 2015).
GABAB receptors are primarily found in the thalamus, hippocampus, and
cerebellum (Allen et al., 2015; Padgett & Slesinger, 2010; Wu & Sun, 2015).

Ontogeny of GABA Receptors
GABAA receptors have a complex pattern of development, in situ
hybridization of tissue sections in rodents reveals differences in the pattern of
expression across ontogeny. In Purkinje cells, 1, 2, 3 and 2 are persistently
expressed from birth to adulthood (Laurie, Wisden, & Seeburg, 1992; Ma et al.,
1993; Zdilar et al., 1992). In the cortex and thalamus, expression of subunits 2,
3, 5 and 3 is noted in both embryonic and early postnatal period (Laurie et
al., 1992; Simeone, Donevan, & Rho, 2003). In the spinal cord, subunits 4 and
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1 are expressed during the embryonic period, weakly detected after birth, and
are almost absent in adulthood (Ma et al., 1993). In the mantle zone of the spinal
cord, subunit 3 is expressed transiently during the embryonic period and
postnatally (Ma et al., 1993). In the cerebellar cortex, subunit 1 demonstrates
low expression in the first postnatal week, decreased expression in the second
postnatal week and is minimally expressed in the third week (Zdilar et al., 1992).
Peak expression of subunits 2, 3, 3, and 2 occurs between the late
embryonic and early postnatal period (Ma et al., 1993; Zdilar et al., 1992).
In situ hybridization revealed a differential expression of GABA B receptor
subtypes in the developing rat spinal cord. Both GABA subtypes were present at
birth, but GABAB1 receptors exhibited increased expression across postnatal
development, while GABAB2 receptors decreased in number (Sands et al., 2003).
Expression of GABAB2 receptors was less robust than GABAB1 across all ages
(Sands et al., 2003).

Glutamate Receptors
Glutamate exerts its effects through two classes of receptors: ionotropic
and metabotropic receptors. The three glutamate ionotropic receptors are amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), N-methyl-Daspartate (NMDA), and kainate (Roberto & Varodayan, 2017). The ionotropic
receptors are nonselective cation channels allowing the passage of Na+ and K+
and, in some instances, Ca2+ (Meyer & Quenzer, 2005). AMPA receptors can be
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found in the hippocampus, cerebral neocortex, cerebellum, retina and thalamic
reticular nucleus, while NMDA receptors are detected in the substantia nigra,
brain stem, and spinal cord (Gereau & Swanson, 2008). Kainate receptors are
predominantly found in the spinal cord, but also mediate responses in the
amygdala, thalamus, and the mossy fibers of the hippocampus (Gereau &
Swanson, 2008)
Glutamate has eight metabotropic receptors (mGluR 1-8). These
receptors are G-protein coupled and are classified into three groups: group one
includes mGluR 1 and 5, group two consists of mGluR 2 and 3, and group three
is made up of mGluR 4, 6, 7, and 8 (Gereau & Swanson, 2008). MGluR 1 and 5
are coupled to Gq, and are primarily postsynaptic; whereas, mGluR 2-4, 6, and 7
are coupled to Gi/Go and are generally presynaptic (Gereau & Swanson, 2008).
Through their coupling to G proteins MGluR 1 and 5 increase the excitability of
postsynaptic cells, whereas mGluR 2-4, 6, and 7, are inhibitory (Conn & Pin,
1997).
Similar to the glutamate ionotropic receptors, mGluRs have a
heterogenous distribution throughout the CNS. MGluR 1 is expressed in the
globus pallidus, olfactory bulb, thalamus, basal ganglia, substantia nigra,
amygdala, hypothalamus, medulla, cerebellum, and the CA1 and CA3 regions of
the hippocampus (Catania et al., 1994; Gereau & Swanson, 2008). MGluR 2 is
expressed in the hippocampus and thalamus. MGluR 3 is distributed in the
retina, thalamus, basal ganglia, corpus collosum, trigeminal nerve, and spinal
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cord (Catania et al., 1994; Gereau & Swanson, 2008). MGluR 4 has a patchy
distribution, with receptors in the thalamus, striatum, and cortex (Catania et al.,
1994). MGluR 5 can be found in the olfactory bulb, caudate, cortex,
hippocampus, globus pallidus, and nucleus accumbens (Catania et al., 1994;
Gereau & Swanson, 2008). MGluR 6 has the most restrictive expression, being
found in only the retina (Gereau & Swanson, 2008). MGluR 7 is expressed in the
hippocampus, ventral pallidum, thalamus, hypothalamus, basal ganglia, brain
stem, and spinal cord (Gereau & Swanson, 2008). Lastly, mGluR 8 can be found
in the olfactory bulb, neocortex, hippocampus, amygdala and cerebellum
(Gereau & Swanson, 2008).

Ontogeny of Glutamate Receptors
AMPA receptors are not common in early embryonic days, but increase in
numbers postnatally (Brennan, et al., 1997; Cristóvão, Oliveira, & Carvalho,
2002), while NMDA receptors are abundant in early postnatal development and
decrease in adulthood (Gereau & Swanson, 2008). There is a notable
developmental shift in the expression of the glutamate metabotropic receptors.
Catania et al. (1994) reported that mGluR1, mGluR2 and mGluR4 receptors are
low in expression at birth, but increase gradually with maturation, while mGluR3
and mGluR5 receptors are expressed at birth in high levels but decline with
increasing age (Catania et al., 1994; Gereau & Swanson, 2008).
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CHAPTER SIX:
MONOAMINE NEUROTRANSMITTERS
Monoamines are small molecular weight neurotransmitters that mediate a
variety of physiological and homeostatic functions (Jaber et al.,1996; Kopin,
1968). Monoamines contain an amino group that is connected to an aromatic ring
by a two-carbon chain (Kopin, 1968). There are different types of monoamine
neurotransmitters: catecholamines and indolamines. Catecholamines contain a
catechol group and a side chain amine and are derived from the amino acid
tyrosine. This group of neurotransmitters includes DA, NE and epinephrine
(Kopin, 1968). The indoleamine, serotonin, derives from the amino acid Ltryptophan (Fidalgo, Ivanov, & Wood, 2013; Coulombe & Sharma, 1986). These
monoamine neurotransmitter systems are relevant to the present study; thus,
they will be further discussed in the sections to follow.

The Dopamine System
DA was once thought of as only a precursor for epinephrine and
norepinephrine (Goldstein, 2010; Kopin, 1968), but DA is now recognized as an
important catecholamine neurotransmitter (Jaber et al.,1996). DA is involved in a
variety of functions, including locomotion, emotions, memory, and
neuroendocrine secretion (Jaber et al.,1996). DA imbalance and dysfunction are
associated with neurological and psychiatric disorders, such as attention-deficit
hyperactivity disorder, schizophrenia, and drug addiction (Jaber et al.,1996;
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Kobayashi, 2001), while degeneration of DA neurons can lead to the
neurodegenerative disorder Parkinson’s disease (Jaber et al.,1996). DA was first
synthesized in 1910 by George Barger and James Ewen at Wellcome
Laboratories (Goldstein, 2010). DA was identified as a neurotransmitter by Arvid
Carlsson and Nils-Ake Hillarp in 1958 (Goldstein, 2010).

Dopamine Synthesis, Release, and Catabolism
DA is synthesized in the terminal of the presynaptic neuron, in a two‐step
process. The biosynthesis of DA begins with the conversion of L-tyrosine to Ldihydroxyphenylalanine (L-DOPA) by the cytosolic enzyme tyrosine hydroxylase.
In turn, L-DOPA is converted into DA by aromatic amino acid decarboxylase
(AADC) (Fernstrom & Fernstrom, 2007; Nagatsu, Levitt, & Udenfriend, 1964).
Tyrosine hydroxylase is the rate limiting step in the synthesis of DA and controls
the rate of synthesis due to its availability (Fernstrom & Fernstrom, 2007). DA
signaling and distribution are dynamically regulated by several factors. Following
synthesis, VMAT2 transports DA from the cytoplasmic space into synaptic
vesicles (German et al., 2015). DA is released into the synaptic cleft via calciumdependent exocytosis (Tritsch & Sabatini, 2012). Once released, DA can bind to
and activate both pre- and postsynaptic DA receptors (German et al., 2015). The
termination of DA neurotransmission is initiated by the reuptake of DA back into
the terminal via DAT (German et al., 2015; Meiser, Weindl, & Hiller, 2013). DA
can then be metabolized by monoamine oxidase (MAO) into 3,4dihydroxyphenylacetaldehyde (DOPAL) (Meiser et al., 2013). DOPAL can be
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further oxidized into carboxylic acid 3,4-dihydroxyphenylacetic acid (DOPAC) via
ALDH (Meiser et al., 2013). DOPAC is converted to homovanilic acid (HVA) via
catechol-O-methyl transferase (COMT) (Meiser et al., 2013).

Dopamine Innervation
In the CNS, cell bodies of DA neurons are found in the mesencephalon,
diencephalon, olfactory bulb, and retina (Binder et al., 2001). The neuronal
projections from these brain areas give rise to four major dopaminergic
pathways: the nigrostriatal, mesolimbic, mesocortical, and tuberoinfundibular
pathways. The nigrostriatal pathway originates in the substantia nigra pars
compacta and ascends to the striatum where it terminates. The nigrostriatal
pathway plays a crucial role in motor control, and damage to this pathway results
in Parkinson’s disease (Binder et al., 2001). The pathway that mediates reward
and motivation is referred to as the mesolimbic pathway, which encompasses
neurons projecting from the ventral tegmental area to the nucleus accumbens,
amygdala, and olfactory tubercule (Binder et al., 2001; Opland, Leinninger, &
Myers, 2010). The mesocortical DA pathway projects from the ventral tegmental
area to the cerebral cortex, particularly the prefrontal cortex (Compton & Hudzik,
2015; Kobayashi, 2001). The mesocortical pathway is important for motivation,
emotion, and memory formation (Kobayashi, 2001). The last of the major
pathways is the tuberoinfundibular pathway. This pathway projects from the
hypothalamus to the posterior pituitary (Kobayashi, 2001). DA neurons in the
tuberoinfundibular pathway are involved in the development and maintenance of
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the pituitary gland, as well as in gene expression and metabolism of pituitary
peptide hormones (Kobayashi, 2001).

Dopamine Receptors
DA receptors are members of a large G-protein coupled receptor family
(Jaber et al.,1996; Niznik & Van Tol, 1992; Tritsch & Sabatini, 2012). The various
actions of DA are mediated by five receptor subtypes, which are divided into two
major subclasses: D1-like and D2-like receptors. Dopaminergic receptors are
classified on the basis of physiological, pharmacological and biochemical criteria
(Jaber et al., 1996; Kebabian & Calne, 1979). D1 and D5 receptors are part of the
D1-like receptor family due to their high sequence homology (Jaber et al., 1996).
These receptors are excitatory, because receptor activation stimulate Gs, thereby
increasing adenylyl cyclase activity and subsequently activating cyclic adenosine
monophosphate (cAMP) dependent protein kinases (Niznik & Van Tol, 1992).
D1-like receptors are mostly found post-synaptically and are more abundant than
D2-like receptors (Jaber et al., 1996). The D2-like family is made up of the D2, D3
and D4 receptor subtypes (Gerfen et al., 1990). In contrast to D1-like receptors,
D2-like receptors are inhibitory. D2-like receptors were first discovered in the
pituitary gland and they inhibit adenylyl cyclase (Niznik & Van Tol, 1992; Jaber et
al., 1996). D2-like receptors bind to the inhibitory G-proteins, Gi and Go, and
decrease cAMP formation. While D1-like receptors are only found on the postsynaptic side, D2-like receptors are localized both pre- and post synaptically
(Niznik & Van Tol, 1992).
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Ontogeny of Dopamine Receptors
Research on D1-like and D2-like receptors in the mammalian rat brain has
revealed that both of these receptor subtypes are present at birth, but their
pattern of development differs (McDougall et al., 2014; Moody & Spear, 1992;
Rao, Molinoff, & Joyce, 1991). Throughout postnatal development the density of
D1-like receptors is consistently higher than D2-like receptors (Gelbard et
al.,1989; Rao et al., 1991). The density of D1-like receptors increases linearly
from PD 1 to 10 followed by a dramatic increase in receptor density from PD 10
to PD 16 (Rao et al.,1991). After this increase, comes a gradual decline until
adult-like levels are reached between PD 28 and PD 40 (Andersen, 2003;
Andersen et al., 2000). On the other hand, D2-like receptor expression increases
linearly between the first and fourth postnatal weeks, they then peak around PD
30 (Rao et al., 1991). Both D1 and D2-like receptors demonstrate peak
expression at PD 40, this being the onset of puberty (Andersen et al., 2000).
Additionally, both subtypes of DA receptors prune by PD 120 (Andersen et al.,
2000).

Norepinephrine
The catecholamine NE is involved in a broad range of functions, such as
attention, memory, mood, endocrine function, and response to stressors
(Goldstein, 2010; Maletic et al., 2017). In 1946, Ulf von Euler was the first to
identify NE as a neurotransmitter (Yamamoto et al., 2014). Dysfunction of NE
systems has been linked to various psychiatric disorders, such as ADHD,
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depression, anxiety, schizophrenia, and post-traumatic stress disorder
(Biederman & Spencer, 1999; Koob, 1999; Yamamoto et al., 2014).

Norepinephrine Synthesis and Inactivation
NE is synthesized from DA in the presence of the enzyme DA hydroxylase, with this conversion occuring within vesicles (Fernstrom &
Fernstrom, 2007; Glowinski & Baldessarini, 1966; Goldstein, 2010; Kopin, 1968;
Ressler & Nemeroff, 1999). Once released, NE can bind to pre- or postsynaptic
receptors, or it can be removed via reuptake by its transporter protein NET
(Goldstein, 2010; Ressler & Nemeroff, 1999; Wassall, Teramoto, & Cunnane,
2009). NE can be metabolized in two ways, first, NE that has been transported
back into the axon terminal is catabolized via MAO, which converts NE into either
3,4-dihydroxyphenylglycol (DHPG) or 3,4-dihydroxymandelic acid (DHMA).
Second, NE can go through enzymatic degradation by COMT, which catabolizes
NE into its metabolite normetanephrine (Ressler & Nemeroff, 1999; Wassall et
al., 2009).

Norepinephrine Innervation
Noradrenergic pathways originate in the locus coeruleus (LC) and project
to many parts of the brain, including the frontal cortex, cerebellum, amygdala,
hippocampus, basal ganglia, thalamus, and hypothalamus (Maletic et al., 2017;
Ressler & Nemeroff, 1999; Sara, 2009).
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Classification of Norepinephrine Receptors
Adrenergic receptors are found in both the central and peripheral nervous
system (Bylund et al., 1994). There are two types of adrenergic receptors,  and
, both of which are G-protein coupled receptors (Bylund et al., 1994; Cotecchia
et al.,1990; Maletic et. al., 2017). Each receptor type has its own family. The 
receptor family includes the 1 and 2 subtypes (Bylund et al., 1994), while the
1 and 2 receptors each have three subtypes: 1A, 1B, and 1D; 2A, 2B,
and 2C (Bylund et al., 1994; Kobilka, 2011; Maletic et al., 2017). The second
major class of adrenergic receptors, , has three subtypes: β1, β2, and β3
(Bylund et al., 1994; Maletic et. al., 2017). Adrenergic 1 and β receptors have a
stimulatory effect on cAMP, while adrenergic 2 receptors have an inhibitory
effect on cAMP signaling by interacting with the Gi/Go proteins (Happe et al.,
1999; Maletic et al., 2017; Sara, 2009).

Ontogeny of Norepinephrine Receptors

Research has revealed differences in the developmental pattern of
adrenergic receptors. 2 Adrenergic receptors in rat brain are widely expressed
at birth, even in brain regions that have low expression in adulthood (e.g., white
matter, cerebellum and the brainstem) (Happe et al., 2004). 2 Adrenergic
receptors reach their peak expression in many brain regions around PD 15, while
in other regions they mature later at PD 28 (basomedial amygdala, lateral
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septum and hippocampal formation) (Happe et al., 1999, 2004). Unlike 2
adrenergic receptor development, levels of β1 and β2 adrenergic receptors are
low at PD 1 and increase over time (Pittman, Minneman, & Molinoff, 1980). In the
cerebral cortex of the rat brain,  adrenergic receptor density increases rapidly
between PD 7-21, after which receptor density remains constant and then begins
to decline at PD 42 (Harden et al., 1977; Pittman et al., 1980). In the cerebellum,
 adrenergic receptor density increases slowly and steadily from PD 5-42, and
the density of receptors remains constant until approximately PD 180 (Pittman et
al., 1980).

Serotonin
Serotonin, also known as 5-hydroxytryptamine (5-HT), is found in both the
CNS and peripheral nervous system. This monoamine plays a key role in sleep,
sexual behavior, mood, and cognition (Fidalgo et al., 2013; Żmudzka et al.,
2018). The majority of 5-HT, an estimated 95%, is produced in the digestive tract
(Fidalgo et. al., 2013; McCorvy & Roth, 2015), while the 5-HT found in the brain
is produced by tryptophan hydroxylase 2 (TPH2) in the raphe nucleus (Muller,
Anacker, & Veenstra-VanderWeele, 2016). The 5-HT system is linked to a variety
of disorders, including Parkinson’s disease, Alzheimer’s disease, depression,
anxiety, schizophrenia, obsessive-compulsive disorder, bipolar disorder, and,
more recently, autism spectrum disorder (López-Figueroa et al., 2004; Muller et
al., 2016; Żmudzka et al., 2018).
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Serotonin Synthesis and Reuptake
Serotonin is synthesized in two steps. The initial step is the conversion of
L-tryptophan to 5-hydroxy-L-tryptophan (5-HTP) by the rate-limiting enzyme
tryptophan 5-hydroxylase (Fidalgo et al., 2013). Tryptophan 5-hydroxylase (Tph)
has two isoforms: Tph1 and Tph2 (Fidalgo et al., 2013; Muller et al., 2016). The
second and final step is the conversion of 5-HTP to 5-HT via AADC. AADC is
also involved in DA synthesis (Fidalgo et al., 2013). 5-HT is released from its
vesicles through Ca2+-dependent exocytosis; once released, it can bind to pre- or
postsynaptic 5-HT receptors (Fidalgo et al., 2013; Filip & Bader, 2009). 5-HT is
rapidly removed from the synaptic cleft by a reuptake process that involves the 5HT transporter (SERT) (Fidalgo et al., 2013). 5-HT is catalyzed by monoamine
oxidase A (MAOA) to yield 5-hydroxyindoleacetic acid (5-HIAA) (Fidalgo et al.,
2013; Muller et al., 2016; Squires et al., 2007).

Serotonin Innervation
The 5-HT system is widespread, with the majority of cell bodies located in
the dorsal and median raphe nuclei of the caudal midbrain (Carolyn et al., 1998;
Fidalgo et al., 2013). 5-HT axons project to the thalamus, hypothalamus, striatal
regions, cortical regions, medulla, pons, midbrain, cerebellum, and spinal cord
(Carolyn et al., 1998; Fidalgo et al., 2013).

Classification of Serotonin Receptors
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5-HT has a large family of receptors, with a total of seven types (5-HT1-7)
(Żmudzka et al., 2018). The majority of these receptors are G-protein coupled
receptors, with the exception of 5-HT3, which is a ligand-gated ion channel (Filip
& Bader, 2009; McCorvy & Roth, 2015). 5-HT1 and 5-HT5 receptors are couple to
the Gi protein. The 5-HT1 receptor type has five subtypes (5-HT1A, 5-HT1B, 5HT1D, 5-HT1E, and 5-HT1F), while the 5-HT5 receptor has two subtypes (5-HT5A
and 5-HT5B) (McCorvy & Roth, 2015). The protein Gq/11 is coupled to 5-HT2
receptors, which includes three subtypes: 5-HT2A, 5-HT2B, and 5-HT2C. These 5HT2 receptors activate phospholipase C, thereby producing inositol triphosphate
(IP3) and diacylglycerol (DAG), which increases intracellular calcium (McCorvy &
Roth, 2015). The Gs coupled receptors include 5-HT4, 5-HT6, and 5-HT7.
Stimulation of the Gs coupled receptors increases cAMP levels (McCorvy & Roth,
2015). The 5-HT3 receptor family includes the isoforms 5-HT3A, 5-HT3B, 5-HT3C,
5-HT3D and 5-HT3E (Filip & Bader, 2009).

Ontogeny of the Serotonin System
In rats, 5-HT levels are low at birth, peak around PD 21–30 and then
decline to adult levels (Murrin, Sanders, & Bylund, 2007). Similar to agedependent decreases in 5-HT levels (Fidalgo et al., 2013), there is evidence of
altered levels of 5-HT receptors across ontogeny. In the cerebellum, 5-HT1 and
5-HT3, receptors reach peak expression levels between PD 7 and PD 12, while 5HT2 receptors peak two weeks after birth and sustain maximal expression until
ten weeks postnatally (Oostland & van Hooft, 2013). In the brain stem, 5-HT1
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receptors are expressed at higher than adult levels at birth, but decrease to adult
levels by PD 15 (Murrin et al., 2007). As a whole, 5-HT2 receptors exhibit peak
expression around PD 13 and then decline to adult levels (Murrin et al., 2007).
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CHAPTER SEVEN:
SUMMARY AND HYPOTHESIS
ADHD is a highly prevalent developmental disorder characterized by
impulsiveness, inattention, and hyperactivity across multiple settings (Baumeister
et al., 2012; Kiely, 2015; Russell, 2011). The etiology of this neurodevelopmental
disorder is unclear, but is thought to have genetic, neurochemical, and
environmental origins. Dysregulation of the central monoamine neurotransmitters
has long been suspected to underlie the pathophysiology of ADHD, primarily
because of the efficacy of AMP and MPH (Curatolo et al., 2010; Oades, 1987). In
addition, a number of allelic variations involving the dopaminergic system, such
as DAT, DRD4, and DRD5 are associated with a diagnosis of ADHD (Curatolo et
al., 2010; Peadon & Elliott, 2010). More recently, prenatal exposure to alcohol
has been strongly associated with a later diagnosis of ADHD (O’Malley &
Nanson, 2002).
Interestingly, while there is a strong link between prenatal alchohol and
ADHD, clinical observations of children with ADHD suggest that the
neurobehavioral disorder caused by prenatal alcohol differs from idiopathic
ADHD (Peadon & Elliot, 2010). Specifically, children exposed to prenatal alcohol
have an earlier onset of ADHD symptoms, higher rates of inattention symptoms,
lower rates of hyperactivity, different neuroanatomical changes, and less of a
clinical response to MPH than AMP (Doig et al., 2008; Glass et al., 2014; O’Neill
et al., 2019; Peadon & Elliott, 2010). These findings suggest that ADHD caused
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by prenatal alcohol exposure may be a special subtype of ADHD or is a
completely different disorder.
In summary, clinical and pre-clinical studies suggest that dopaminergic
dysfunction and alcohol exposure both lead to ADHD-like symptoms, such as
hyperactivity, impulsivity and deficits in executive function. While many children
with fetal alcohol spectrum disorder (FASD) have ADHD symptoms, the
relationship between the two is not well understood. In particular, the effects of
pre-existing DA dysfunction in combination with early alcohol exposure is
unknown. To gain insight on this relationship, this thesis assessed the effects of
early alcohol exposure on normal and DA-deficient rats.
To this end, we measured DA content, basal and psychostimulant-induced
locomotor activity, and passive avoidance learning in DA-deficient rats, alcohol
exposed rats, and a combined group that consisted of rats with both a DA
deficiency and alcohol exposure. Rats were assessed during preadolescence
(PD 20-26), since previous reports have found more pronounced deficits during
this age span (Barron & Riley, 1990; Dursun et al., 2006; Schneider et al., 2011).
Due to the age of the animals, we do not expect to see sex differences. A total of
12 groups were used in order to precisely determine whether a DA deficiency in
combination with alcohol exposure enhances hyperactivity and impulsivity.
Overall, we had two primary hypotheses. First, we looked at locomotor
hyperactivity by measuring the activity of the rats. We predicted that the alcohol
exposed rats would display locomotor hyperactivity, because this has been
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reported in children and in preweaning and juvenile rats after perinatal exposure
to ethanol (Barron & Riley, 1990; Dursun et al., 2006). We predicted that the DAdeficient rats would show more locomotor hyperactivity when compared to the
alcohol exposed rats. This hypothesis was based on reports from clinical studies
showing that children with prenatal alcohol exposure exhibit lower rates of
locomotor hyperactivity than children with ADHD (Glass et al., 2014). Lastly, we
hypothesized that the combined group would exhibit increased locomotor
hyperactivity, relative to the other two groups. Additionally, AMP- and MPHinduced changes in locomotion were compared. The purpose of this experiment
was to determine whether findings using this rodent model were consistent with
results obtained in clinical populations with this subtype of ADHD. We predicted
that DA-deficient rats would have a similar response to AMP and MPH. We
anticipated that the alcohol exposed group and the combined group would show
less of a response to MPH than AMP. This hypothesis was based on clinical
evidence demonstrating that humans exposed to alcohol at an early age
responded better to AMP than to MPH (Peadon & Elliott, 2010).
Second, this thesis assessed learning impairments and impulsivity via the
passive avoidance learning task. The passive avoidance task is used to assess
aspects of executive function, such as learning and memory (Hausknecht et al.,
2005; Schneider et al., 2011) as well as inhibitory control (Abel, 1982; Barron &
Riley, 1990; Bizot & Thiébot, 1996; Cronise et al., 2001; Dursun et al., 2006). In
this task, animals learn to avoid an aversive stimulus by inhibiting a previously
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punished response (Abdel-Mouttalib, 2015). We predicted that DA-deficient rats
would show poor passive avoidance learning. This hypothesis was based on past
findings demonstrating that 6-OHDA lesioned rats exhibit learning impairments in
similar tasks (Russell, 2011; Sagvolden et al., 2005; Stanford & Tannock, 2011).
We expected alcohol exposed rats to show more profound deficits on the passive
avoidance task than 6-OHDA rats. This hypothesis was based on evidence from
previous studies showing that alcohol exposure during the neonatal period
results in a lack of response inhibition during early adolescence (Abel, 1982;
Barron & Riley, 1990; Cronise et al., 2001; Dursun et al., 2006). Lastly, it was
hypothesized that a 6-OHDA lesion in combination with neonatal alcohol
treatment would result in a greater inability to withhold responding when
compared to alcohol exposed rats or DA-deficient rats.

42

CHAPTER EIGHT:
METHODS
Subjects
Subjects were 1,053 male and female rats (Charles River, Hollister, CA) of
Sprague-Dawley descent. All subjects were born and raised at California State
University, San Bernardino (CSUSB). The day of parturition was considered PD
0. Beginning on PD 3, each rat was given a distinctive tail mark using colored
nontoxic markers. The subjects were given unlimited access to both food and
water throughout the study. Pups were kept with the dam until PD 26 in a
climate-controlled vivarium maintained at 22-24°C and kept under a 12:12h
light/dark cycle. All subjects were cared for according to the “Guide for the Care
and Use of Laboratory Animals” (National Research Council, 2010) under a
research protocol approved by the Institutional Animal Care and Use Committee
of CSUSB.

Drugs

Desipramine hydrochloride, 6-hydroxydopmaine (6-OHDA),
methylphenidate, and amphetamine were obtained from Sigma-Aldrich (St.
Louis, MO). 6-OHDA was mixed in a sterile saline solution containing 0.1%
ascorbic acid. Methylphenidate and amphetamine were dissolved in saline at a
volume of 2.5 ml/kg. Ethanol (Decon Labs, Inc., 100% USP certified) was mixed
in a commercially available milk solution (Enfamil Premium Infant Formula, Mead
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Johnson). Powder Enfamil was mixed with distilled water according to the
manufacturer’s directions to make 60 ml each day (8.9 g powder in 60 ml of
water). Ethanol was diluted with the milk solution to make 0.3 g/kg and 3 g/kg
solutions and was stored in the refrigerator until used. Ethanol and milk solutions
were given orally, at a volume of 19 ml/kg. Unused ethanol and milk solutions
were discarded at the end of each day.

Apparatus

Locomotor Activity
Behavioral testing was done in activity monitoring chambers (26 x 26 x 41
cm) that consist of a plastic floor, acrylic walls, and an open top. Distance
traveled was measured.
Passive Avoidance
Passive-avoidance testing occurred in clear Plexiglas shuttle boxes
divided into two equal compartments (14 x 7 x 12cm) separated by a guillotine
door. One of the chambers was transparent and the other was dark and opaque.
The flooring of the boxes was composed of stainless-steels bars. A Coulbourn
solid-state shock generator delivered a 0.5-mA pulse of distributed shock to the
floor of the black compartment.

Procedure
6-OHDA Microinjection
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On PD 3, culled rats were given an injection of desipramine (25 mg/kg, IP)
to preserve noradrenergic neurons. After 45 min, pups received a topical
anesthetic (4% lidocaine solution) and were injected (IC) with 10 µL of 6-OHDA
or vehicle at a depth of 0.4 cm using a 30-gauge needle attached to a 25 µL
Hamilton microsyringe. The needle was inserted into the foramen magnum
between the occipital bone and the first cervical vertebra. Following the 6-OHDA
microinjection procedure, pups were returned to their home cages.
Intragastric Intubation Feeding
Daily intragastric intubations occurred from PD 4-9. Weight was recorded
on each day of feeding. Pups were placed on a heating pad for the duration of
the intubation procedure. Intubations were administered using PE 10 Intramedic
tubing connected to a syringe (1 mL with a 23-guage needle) via a small piece of
PE 50 Intramedic tubing. The PE 10 tubing was marked prior to the start of
intubation, in order to indicate the distance necessary to reach the stomach. Rat
pups were held securely so their esophagus was in linear plane. The PE 10
tubing was dipped in corn oil to ease the stress of intubation. The tubing was
inserted so that it moved over the tongue and follows the roof of the mouth, to the
throat, and down to the stomach.
Dopamine Content Assay
On PD 21, 6-OHDA and alcohol treated animals were euthanized by rapid
decapitation and their striatum was removed and stored for future analysis of DA
levels. The striatum of each subject was stored at -80 °C. During the DA content
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assay, frozen tissue was sonicated and dissolved in 10 volumes of 0.1 N HClO4
and centrifuged at 20,000 x g for 30 min at 4 °C. Resulting supernatant was
filtered through a 0.22 µm centrifugation apparatus at 2,000 x g for 5 min at 4 °C.
The resulting extracts (20 µL) were assayed for DA content using high
performance liquid chromatography with electrochemical detection (Coulochem
II; ESA). The mobile phase was comprised of 75 mM NaH2PO4, 1.4 mM 1-octane
sulfonic acid, 10 mM EDTA, and 10% acetonitrile [(pH 3.0) MD-TM Mobile
Phase; ESA] and pumped at a rate of 0.5 mL per min.
Experiment 1: Comparison of Dopamine Depletion, Early Alcohol Exposure, or
Combined Treatment on Basal and Psychostimulant-Induced Locomotor Activity
Male and female animals were randomly assigned to one of 36 groups (n=
9). The first independent variable was lesion, with three levels (no lesion, sham,
or 6-OHDA). The second independent variable was intubation, with four levels
(no intubation, 0, 0.3, or 3 g/kg ethanol). The third independent variable was
psychostimulant treatment with three levels (saline, methylphenidate or
amphetamine).
On PD 19, male and female rats were habituated to the locomotor activity
chambers and then returned to their home cage. The following day (PD 20) male
and female rats were injected intraperitoneally (ip) with saline, methylphenidate
(2.5 mg/kg) or amphetamine (1 mg/kg). On both days, locomotor activity was
measured for 60 min. The design of Experiment 1 is shown in Table 1.
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Table 1. Design of Experiment 1

LESION

INTUBATION

DRUG

No lesion

No Intubation

Saline, MPH, or AMP

No lesion

0 g/kg ethanol

Saline, MPH, or AMP

No lesion

0.3 g/kg ethanol

Saline, MPH, or AMP

No lesion

3 g/kg ethanol

Saline, MPH, or AMP

Sham

No Intubation

Saline, MPH, or AMP

Sham

0 g/kg ethanol

Saline, MPH, or AMP

Sham

0.3 g/kg ethanol

Saline, MPH, or AMP

Sham

3 g/kg ethanol

Saline, MPH, or AMP

6-OHDA

No Intubation

Saline, MPH, or AMP

6-OHDA

0 g/kg ethanol

Saline, MPH, or AMP

6-OHDA

0.3 g/kg ethanol

Saline, MPH, or AMP

6-OHDA

3 g/kg ethanol

Saline, MPH, or AMP

Experiment 2: Comparison of Dopamine Depletion, Early Alcohol Exposure, or
Combined Treatment on Passive Avoidance Learning
Male and female animals were randomly assigned to one of twelve groups
(n= 10). On PD 23, subjects began training on a step-through passive avoidance
task. Acquisition occurred on PD 23 and retention of the passive avoidance was
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assessed on the following three days. On the acquisition day, the rat was placed
in the clear illuminated compartment with the guillotine door closed. After 30 s,
the door opened. Movement to the adjoining chamber resulted in closure of the
dividing door and delivery of a brief (3 s) foot shock (0.5-mA). Latency for the rat
to cross from the clear to the dark compartment was recorded. After 30 s, the rat
was removed from the testing chamber and returned to the home cage.
Retention was assessed after an interval of 24 h (PD 24), 48 h (PD 25), and 72 h
(PD 26). Specifically, rats were placed in the clear illuminated compartment with
the door open and the latency to leave the illuminated chamber was measured.
No shock was administered on retention trials. Retention trials were discontinued
after 600 s if the rat did not move into the dark compartment.

Table 2. Design of Experiment 2
LESION

INTUBATION

No lesion

No Intubation

No lesion

0 g/kg ethanol

No lesion

0.3 g/kg ethanol

No lesion

3 g/kg ethanol

Sham

No Intubation

Sham

0 g/kg ethanol
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Sham

0.3 g/kg ethanol

Sham

3 g/kg ethanol

6-OHDA

No Intubation

6-OHDA

0 g/kg ethanol

6-OHDA

0.3 g/kg ethanol

6-OHDA

3 g/kg ethanol

Data Analysis
DA Content
DA and DOPAC were analyzed by separate 3 x 4 x 2 (lesion x alcohol x
sex) three-way ANOVAs. Post hoc analysis of the neurochemical data was made
using Tukey tests (p <.05).
Experiment 1
Basal locomotor activity (distance traveled) was analyzed by a 2 x 3 x 4
(sex x lesion x alcohol) three-way ANOVA. Significant higher-order interactions
were further analyzed using one- or two- way ANOVAs. Post hoc analysis of the
behavioral data was made using Tukey tests (p <.05)
Psychostimulant-induced locomotor activity (distance traveled) was
analyzed by a 2 x 3 x 4 x 3 (sex x lesion x alcohol x drug) four-way ANOVA.
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Significant higher-order interactions were further analyzed using one- or two- way
ANOVAs. Post hoc analysis of the behavioral data was made using Tukey tests
(p <.05). Litter effects were controlled by assigning no more than one rat from
each litter to a particular group.
Experiment 2
Passive avoidance data were analyzed using a 2 x 3 x 4 x 4 (sex x lesion
× alcohol x day) mixed factors ANOVA, with sex, lesion, and alcohol being
between-subject factors and day being a within-subject repeated measures
factor. Mauchly’s test was used to detect violations of the sphericity assumption.
When violations of sphericity were detected, the Huynh-Feldt Epsilon statistic
was used to make corrections. When appropriate, post-hoc analyses were
conducted using Tukey tests (p <.05).
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CHAPTER NINE:
RESULTS
Experiment One
Habituation Day
On the habituation day, lesion condition significantly impacted locomotor
activity because rats that received 6-OHDA lesions had larger distance traveled
scores than rats in the sham or no lesion groups [Lesion main effect, F(2,614) =
57.38, p<.001] (see Figure 1). The 6-OHDA lesion (M = 6035.63, SEM = 186.72)
significantly increased the distance traveled scores of rats when compared to
sham lesion (M = 3592.21, SEM = 181.34) and no lesion rats (M = 3629.98, SEM
= 180.53). Neither sex nor early exposure to alcohol altered locomotor activity
(see Figure 2). In addition, sex, lesion and alcohol did not interact to affect basal
locomotor activity.
Further analyses showed that there were no significant differences
between the two lesion control groups (i.e., sham and no lesion) and the two
alcohol control groups (no intubation and only milk). Thus, the separate control
groups were combined to form a single lesion control group and a single alcohol
control group for subsequent analyses.
Test Day
On the test day, locomotor activity was greatly increased by the
psychostimulants (amphetamine or methylphenidate) [Drug main effect, F(2,557)
= 410.52, p<.001 (see Figure 3). The effects of amphetamine (1mg/kg) (M =
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20661.70, SEM = 474.40) and methylphenidate (2.5 mg/kg) (M = 22169.99, SEM
= 487.52) did not significantly differ from one another. The effects of saline (M =
4736.14, SEM = 473.77) were significantly different than that of amphetamine
and methylphenidate.
The effect of psychostimulant administration on locomotor activity was
altered by sex, lesion condition, and alcohol exposure [Sex × Lesion × Alcohol ×
Drug interaction, F(4,593) = 2.46, p<.05]. To interpret the meaning of the fourway interaction, separate ANOVAs were conducted for each drug treatment.
Saline Treatment. Similar to the habituation day, rats given 6-OHDA
lesions exhibited greater locomotor activity than lesion controls [Lesion main
effect, F(1,202) = 31.55, p<.001] (see Figure 4). The 6-OHDA lesion (M =
6518.14, SEM = 3831.95) significantly increased the distance traveled scores of
rats when compared to lesion controls (M = 3818.7007, SEM = 2590.26). This
effect of lesion was affected by both sex and alcohol condition [Sex × Lesion ×
Alcohol interaction, F(2,202) = 3.40, p<.05] (see Figure 4). Specifically, when
only female rats were analyzed, non-lesioned rats treated with the low dose of
alcohol (0.3 g/kg), had increased distance traveled scores as compared to
female rats in the alcohol control or high dose alcohol groups, [Alcohol effect,
F(2,72) = 10.64, p<.001, and Tukey tests, p<.05] (see Figure 4).
Amphetamine Treatment. Sex significantly impacted the rat’s response to
AMP [Sex main effect, F(1,201) = 4.95, p<.05] (see Figure 5). Male rats (M =
22341.32, SEM = 900.62) given AMP had greater distance traveled scores than
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female rats (M = 19502.98, SEM = 904.38). In contrast to my predictions, the
effect of sex was not significantly affected by lesion or alcohol condition [Sex ×
Lesion × Alcohol interaction, F(2,201) = 2.70, p=.07, ns] (see Figure 5).
Methylphenidate Treatment. Male rats (M = 23154.18, SEM = 872.46) that
received MPH on the test day had higher levels of locomotor activity than female
rats (M = 21233.07, SEM = 749.38), [Sex main effect, F(1,190) = 6.77, p<.05]
(see Figure 6). This increased locomotor activity in male rats was most
pronounced in rats that received 6-OHDA lesions [Sex × Lesion interaction,
F(1,190) = 4.16, p<.05] (see Figure 6), because further analyses showed MPHtreated male rats with 6-OHDA lesions had greater distance traveled scores than
MPH-treated female rats with 6-OHDA lesions [Sex main effect, F(1,57) = 6.99,
p<.05] (see Figure 6).
Monoamine Assays
DA Levels. As expected, there were significant differences in striatal DA
levels as a result of 6-OHDA lesions [Lesion main effect, F(2,190) = 375.23,
p<.001 and Tukey tests p<.001] (see Figure 7). Specifically, the 6-OHDA lesion
group (M = 1.68, SEM = .20) had significantly lower levels of DA than both the
sham lesion (M = 6.95, SEM = .17) and the no lesion group (M = 6.82, SEM =
.15). Alcohol did not affect DA levels, [Alcohol main effect, F(3,190) = 2.59,
p=0.054, ns] (see Figure 7). While not significant, the low dose of alcohol (0.3
mg/kg) appeared to produce a small reduction in DA levels, when compared to
the control and high alcohol groups.
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DOPAC Levels. Rats given 6-OHDA lesions (M = .39, SEM = .03) had
reduced striatal DOPAC levels when compared to the sham (M = 1.36, SEM =
.05) and no lesion group (M = 1.29, SEM = .04), [Lesion main effect, F(2,190) =
208.58, p<.001, and Tukey tests, p<.001] (see Figure 8). Alcohol treatment did
not significantly impact striatal DOPAC levels [p=.29].

Experiment Two
Passive Avoidance Training
All rats responded similarly on the conditioning trial, since the time to enter
the dark chamber was unaffected by sex, lesion treatment or alcohol exposure.
Furthermore, rats in all groups had significantly greater latencies to enter the
dark chamber after the conditioning trial, thus demonstrating that the rats learned
and retained the passive avoidance task on all four retention test days [Day main
effect, F(3, 621) = 53.719, p<0.001] (see Figure 9). Because the latency times
were significantly affected by day, further analyses were conducted separately
for each test day.
Test Day 1. On the first test day, step-through latencies were significantly
shorter for rats lesioned with 6-OHDA (M = 72.07, SEM = 12.72), as compared to
the no lesion control group (M = 191.13, SEM = 21.75), [Lesion main effect, F(2,
207) = 10.357, p<0.001, Tukey tests, p<0.05] (see Figure 10). Sham lesioned
rats (M = 119.80, SEM = 17.66) had marginally longer latencies when compared
to 6-OHDA lesioned rats, but this difference was not significant. There was also a
non-significant trend for both sex and alcohol to alter the effects of lesion on
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step-through latencies [Sex × Lesion × Alcohol interaction, F(6, 207) = 2.108,
p=0.054]. Specifically, alcohol-exposed male rats in the no lesion condition had
shorter step-through latencies than non-exposed rats in the same lesion
condition.
Test Day 2. Similar to the first test day, 6-OHDA lesioned rats (M = 78.44,
SEM = 15.45) on Test Day 2 had shorter step-through latencies when compared
to rats in the control lesion groups, no lesion (M = 184.86, SEM = 24.43) and
sham lesion (M = 142.23, SEM = 20.95), [Lesion main effect, F(2, 207) = 6.609,
p<0.01, Tukey tests, p<0.05] (see Figure 11). Alcohol exposure and sex did not
affect step-through latencies on Test Day 2.
Test Day 3. On the last test day, once again the 6-OHDA lesion rats (M =
58.49, SEM = 12.74) showed a decrease in latency to move to the dark chamber
when compared to both no lesion (M = 175.01, SEM = 24.35) and sham lesion
(M = 141.00, SEM = 23.47) controls [Lesion main effect, F(2, 207) = 8.484,
p<0.001, Tukey tests, p<0.05] (see Figure 12). This difference in step-through
latencies in the lesion condition was moderated by alcohol treatment [Lesion ×
Alcohol interaction, F(6, 209) = 2.648, p<0.05] (see Figure 12). Specifically, both
male and female rats in the no lesion condition exposed to the high dose of
alcohol (3 g/kg) had shorter latencies than rats in the same lesion condition
exposed to milk only (0 g/kg) [Tukey tests, p<0.05]. Moreover, males in the sham
condition that were exposed to a high dose of alcohol (3 g/kg) had longer stepthrough latencies than male rats in the same lesion condition but not exposed to
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alcohol [Sex × Lesion × Alcohol interaction, F(6, 207) = 2.154, p<0.05, Tukey
tests, p<0.05] (see Figure 12).

56
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No Lesion
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6-OHDA

Figure 1. Experiment 1 Habituation Day
Mean distance traveled scores (± SEM) of male and female rat pups on the
habituation day (PD 19). On PD 3, rats were either untreated (no lesion), given a
sham lesion (sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, ic).
Starting on PD 4, rats received alcohol infusions (0, 0.3 or 3 g/kg) daily or were
unhandled (no intubation) until PD 9. Distance traveled testing occurred on PD
19. ‘a’ Indicates a significant difference relative to the sham and no lesion
groups.
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Figure 2. Experiment 1 Habituation Day
Mean distance traveled scores (± SEM) of male and female rat pups on the
habituation day (PD 19). On PD 3, rats were either untreated (no lesion), given a
sham lesion (sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, ic).
Starting on PD 4, rats also received ethanol infusions (0, 0.3 or 3 g/kg) daily or
were unhandled (no intubation) until PD 9.
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Figure 3. Experiment 1 Test Day
Mean distance traveled scores (± SEM) of male and female rat pups on the test
day (PD 20). On PD 3, Rats were either untreated (no lesion), given a sham
lesion (sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, ic). Starting on
PD 4, rats also received alcohol infusions (0, 0.3 or 3 g/kg) daily or were
unhandled (no intubation) until PD 9. On the test day, rats received saline, AMP
(1 mg/kg, ip), or MPH (2.5 mg/kg, ip) before distance traveled testing.
‘a’ Indicates a significant difference compared to the AMP or MPH groups.
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Figure 4. Experiment 1 Test Day
Mean distance traveled scores (± SEM) of male and female rat pups in the saline
condition on the test day (PD 20). On PD 3, rats were either untreated (no
lesion), given a sham lesion (sham), or lesioned with 6-ODHA infusions (100
μg/10 μl, ic). From PD 4-9, rats were exposed to ethanol (0, 0.3, or 3 g/kg) daily
or were unhandled (no intubation). On PD 20, rats had been injected with saline,
AMP (1 mg/kg, ip), or MPH (2.5 mg/kg, ip) before being placed in the activity
chambers. ‘a’ Indicates a significant difference from the control lesion rats (i.e.,
no lesion and sham). ‘b’ Indicates a significant difference from the no alcohol and
high alcohol (3 g/kg) group.
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Figure 5. Experiment 1 Test Day
Mean distance traveled scores (± SEM) of rats in the amphetamine condition on
test day (PD 20). On PD 3, male and female rats were untreated (no lesion),
given a sham lesion (sham), or lesioned with 6-ODHA infusions (100 μg/10 μl,
ic). From PD 4-9, rats were exposed to ethanol (0, 0.3, or 3 g/kg) daily or were
unhandled (no intubation). On PD 20, rats were injected with saline, AMP (1
mg/kg, ip), or MPH (2.5 mg/kg, ip) before being placed in the activity chambers.
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Figure 6. Experiment 1 Test Day
Mean distance traveled scores (± SEM) of male and female rat pups in the MPH
condition on the test day (PD 20). On PD 3, rats were either untreated (no
lesion), given a sham lesion (sham), or lesioned with 6-ODHA infusions (100
μg/10 μl, ic). From PD 4-9, rats were exposed to ethanol (0, 0.3, or 3 g/kg) daily
or were unhandled (no intubation). On PD 20, rats were injected with saline, AMP
(1 mg/kg, ip), or MPH (2.5 mg/kg, ip) before being placed in the activity chambers
‘a’ Indicates a significant difference from female 6-OHDA rats treated with MPH
(2.5 mg/kg, ip).
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Figure 7. Striatal DA Content
Mean (±SEM) striatal DA content of male and female rat pups on PD 21. On PD
3, rats were either untreated (no lesion), given a sham lesion (sham), or lesioned
with 6-ODHA infusions (100 μg/10 μl, ic). From PD 4-9, rats were exposed to
ethanol (0, 0.3, or 3 g/kg) daily or were unhandled (no intubation).
‘a’ Indicates a significant difference from no lesion and sham lesioned rats.
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Figure 8. Striatal DOPAC Content
Mean (±SEM) striatal DOPAC content of male and female rat pups on PD 21. On
PD 3, rats were untreated (no lesion), given a sham lesion (sham), or lesioned
with 6-ODHA infusions (100 μg/10 μl, ic). Starting on PD 4, rats received ethanol
infusions (0, 0.3 or 3 g/kg) daily or were unhandled (no intubation) until PD 9.
‘a’ Indicates a significant difference from no lesion and sham lesioned rats.
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Figure 9. Step-through Latency on Conditioning Day
Mean step-through latency (± SEM) of male and female rat pups on the
conditioning day (PD 23) and test days 1-3 (PD 24-26). On PD 3, rats were either
untreated (no lesion), given a sham lesion (sham), or lesioned with 6-ODHA
infusions (100 μg/10 μl, ic). From PD 4-9, rats were exposed to alcohol (0, 0.3, or
3 g/kg) daily or were unhandled (no intubation). On PD 23, rats were conditioned
by receiving a shock when they entered the dark chamber. Retention was tested
for three consecutive days (PD 24-26). ‘a’ Indicates a significant difference
relative to the conditioning day.
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Figure 10. Step-through Latency on Test Day 1
Mean step-through latency (± SEM) of male and female rat pups on test day 1
(PD 24). On PD 3, rats were either untreated (no lesion), given a sham lesion
(sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, ic). From PD 4-9, rats
were exposed to alcohol (0, 0.3, or 3 g/kg) daily or were unhandled (no
intubation). On PD 23, rats were conditioned by receiving a shock when they
entered the dark chamber. Retention was tested for three consecutive days (PD
24-26). ‘a’ Indicates a significant difference relative to the no lesion group.
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Figure 11. Step-through Latency on Test Day 2
Mean step-through latency (± SEM) of male and female rat pups on test day 2
(PD 25). On PD 3, rats were either untreated (no lesion), given a sham lesion
(sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, ic). From PD 4-9, rats
were exposed to alcohol (0, 0.3, or 3 g/kg) daily or were unhandled (no
intubation). On PD 23, rats were conditioned by receiving a shock when they
entered the dark chamber. Retention was tested for three consecutive days (PD
24-26). ‘a’ Indicates a significant difference relative to the no lesion group.
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Figure 12. Step-through Latency on Test Day 3
Mean step-through latency (± SEM) of male and female rat pups on test day 3
(PD 26). On PD 3, rats were either untreated (no lesion), given a sham lesion
(sham), or lesioned with 6-ODHA infusions (100 μg/10 μl, ic). From PD 4-9, rats
were exposed to alcohol (0, 0.3, or 3 g/kg) daily or were unhandled (no
intubation). On PD 23, rats were conditioned by receiving a shock when they
entered the dark chamber. Retention was tested for three consecutive days (PD
24-26). ‘a’ Indicates a significant difference relative to the no lesion and sham
group. ‘b’ Indicates a significant difference from the no alcohol group (0 g/kg). ‘c’
Indicates a significant difference from the sham lesion male rats in the unhandled
group.
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Figure 13. Step-through Latency by Lesion
Mean step-through latency (± SEM) of 6-OHDA lesioned male and female rat
pups on the conditioning day (PD 23) and test days 1-3 (PD 24-26). On PD 3,
rats were either untreated (no lesion), given a sham lesion (sham), or lesioned
with 6-ODHA infusions (100 μg/10 μl, ic). From PD 4-9, rats were exposed to
alcohol (0, 0.3, or 3 g/kg) daily or were unhandled (no intubation). On PD 23, rats
were conditioned by receiving a shock when they entered the dark chamber.
Retention was tested for three consecutive days (PD 24-26). ‘a’ Indicates a
significant difference relative to test days (1-3). ‘b’ Indicates a significant
difference from the no lesion rats.
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CHAPTER TEN:
DISCUSSION
Overview
The present thesis examined the individual and combined ability of
neonatal 6-OHDA lesions and early alcohol exposure to induce ADHD-like
symptoms in preweanling rats. In the first experiment, we assessed the
aforementioned treatments on basal and psychostimulant-induced locomotor
activity. We had three hypotheses about the effects of our treatment conditions
on basal locomotion. First, we predicted that alcohol exposed rats, similar to the
DA-deficient rats, would display an increase in locomotor activity, because rats
treated prenatally with alcohol show higher activity than control rats (Barron &
Riley, 1990; Dursun et al., 2006; Hausknecht et al., 2005). Second, we
hypothesized that alcohol exposed rats would exhibit less locomotor activity than
DA-deficient rats. This prediction was based on past research demonstrating that
children with prenatal alcohol exposure exhibit less hyperactivity than children
with ADHD (Glass et al., 2014). Lastly, we hypothesized that rats given the
combined treatment would exhibit greater locomotor hyperactivity than the other
two groups. Additionally, we made predictions about differential responses to
psychostimulant administration after DA depletion and alcohol exposure in rats.
Specifically, we hypothesized that DA-deficient rats would have similar reduced
responses to both AMP and MPH, but that both the alcohol exposed and
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combined group would show less of a response to AMP than to MPH, this
prediction was based on clinical literature (Peadon & Elliott, 2010).
In the second experiment, we assessed the effects of neonatal 6-OHDA
lesions and early alcohol exposure in combination and individually on passive
avoidance learning. We predicted that DA-deficient rats would perform worse
than lesion controls on the passive avoidance task in concordance with past
studies using 6-OHDA lesioned rats (Russell, 2011; Sagvolden et al., 2005;
Stanford & Tannock, 2011). It was also predicted that alcohol exposed rats would
show a more profound deficit on the passive avoidance task when compared to
6-OHDA lesioned rats. This hypothesis was based on past research
demonstrating that alcohol exposure results in a lack of response inhibition (Abel,
1982; Barron & Riley, 1990; Cronise et al., 2001; Dursun et al., 2006). Lastly, it
was hypothesized that combined treatment would produce the greatest deficit on
this task.

Basal Locomotion
The locomotor data revealed that the 6-OHDA lesion resulted in greater
distance traveled in both male and female rats. Additionally, the low dose of
alcohol increased locomotor activity in female rats after habituation to the
chamber. In contrast to our predictions, the combined effects of lesion and
alcohol did not result in any significant increases in locomotor activity.
It is well established that 6-OHDA lesions result in locomotor hyperactivity
in rats (Russell, 2011; Sagvolden et al., 2005; Stanford & Tannock, 2011). Thus,
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the present findings were not unexpected because both male and female rats
lesioned with 6-OHDA had greater distance traveled scores than lesion controls.
On the test day, non-lesioned female rats exposed to the low dose (0.3
g/kg), but not the high dose (3 g/kg), of alcohol, exhibited an increase in
locomotor activity. This finding is novel, as the dose range in alcohol exposure
studies typically falls between 1 and 6 g/kg (Brocardo et al., 2012; Hamilton et
al., 2011; Hausknecht et al., 2017; Juárez & Guerrero-Álvarez, 2015; Patten et
al., 2014; Vaglenova & Petkov, 1998). To our knowledge, no published studies
report alterations in locomotor activity after low dose alcohol treatment. Data on
the effects of early alcohol exposure on locomotor activity is limited and the data
that do exist provide mixed results. For example, some studies report higher
locomotor activity after moderate-dose alcohol exposure (Juárez & GuerreroÁlvarez, 2015), while other studies do not find changes in locomotion (Atalar et
al., 2016; Dursun et al., 2006). The present findings suggest that low-dose
alcohol exposure during the postnatal period may have more impact on activity
levels than higher doses.

Psychostimulant-Induced Locomotion
Overall, treatment with AMP (1 mg/kg) and MPH (2.5 mg/kg) produced
nearly identical levels of locomotor activity. These findings are consistent with our
hypothesis that rats would have a similar response to AMP and MPH. It was also
hypothesized that psychostimulant treatment would reduce locomotor
hyperactivity in the alcohol exposed rats and in the combined group; however,
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our results did not support this hypothesis. Overall, alcohol treatment did not
differentially alter locomotor activity on test day, yet sex and dopamine depletion
did alter the response to the two drugs.
Amphetamine administration produced more locomotor activity in male
rats than female rats. Although not statistically significant, rats exposed to alcohol
showed a trend towards an increased locomotor activity on the test day when
compared to the habituation day. Currently, only a few studies have measured
the effects of psychostimulants on alcohol exposed rats and those studies report
mixed results. One study reported that treatment with AMP resulted in no
differential effect on hyperactivity (Bond, 1985), while another study reported an
increase in activity following AMP treatment (Blanchard, Hannigan, & Riley,
1987). These findings suggest that AMP may enhance activity in alcohol-treated
rats.
Similar to the findings with AMP, male rats treated with MPH were more
active than female rats. 6-OHDA depletion of dopamine enhanced this
difference, as MPH-treated male lesioned rats were more active than MPHtreated female lesioned rats. Alcohol exposure did not significantly alter
locomotor activity in MPH-treated rats; however, when compared to the
habituation day, there was an increase in MPH-induced locomotor activity.
Consistent with our findings, Abel (1993), reported that MPH treatment enhances
the locomotor activity of alcohol exposed rats. Conversely, Juárez and GuerreroÁlvarez (2015) report that MPH has no effect on hyperactivity. Taken together
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these findings suggest that treatment with MPH may not be effective at reducing
hyperactivity in alcohol treated rats.
Our hypothesis that the alcohol exposed group and the combined group
would show a lessened response to MPH, relative to AMP, was not supported.
These findings contrast with clinical evidence showing that humans exposed to
alcohol at an early age respond better to AMP than to MPH (Peadon & Elliott,
2010).

Monoamine Assays
Because decreases in DA content are reliably associated with ADHD as
well as deficits in learning and memory, we hypothesized that alcohol exposure
would induce declines in DA levels similar to 6-OHDA lesions (Jaber et al.,1996;
Kobayashi, 2001). However, our hypothesis was not supported because alcohol
treated rats did not exhibit a decline in DA or DOPAC levels. In contrast, 6OHDA lesions resulted in the expected decrease in DA and DOPAC levels in
preweanling rats (Stanford & Tannock, 2011). In brief, the 6-OHDA lesion
reliably caused a significant decrease in DA and DOPAC levels, whereas the
alcohol treatment did not cause a reduction.

Passive Avoidance
Consistent with past studies, decreasing DA content with 6-OHDA lesions
resulted in impaired performance on the learning task. Specifically, 6-OHDA
lesioned male and female rats had significantly shorter latencies when compared
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to control rats on the step-through passive avoidance task, suggesting that the 6OHDA lesion had an impact on learning inhibitory control and memory. While 6OHDA lesions impair performance on some tasks, only one other study reported
that 6-OHDA lesioned rats exhibited deficits on the passive avoidance task
(Pearson et al., 1980). Like us, Pearson et al. (1980) injected their pups with
desipramine prior to lesioning with 6-OHDA and their injection volumes and age
(PD 27) were similar to our own (Pearson et al., 1980). In contrast several other
studies found that 6-OHDA lesions did not affect passive avoidance performance
(Anderson et al., 1986; Cooper, 1973; Takasuna & Iwasaki, 1996); however,
there were clear methodological differences that could account for the disparate
results, including the dose of 6-OHDA used and age at testing. The current
study used a modest dose of 6-OHDA (100 μg/10 μl), while Cooper (1973) used
twice this dose (240 μg) and also tested the rats at a younger age (PD 14).
Takasuna and Iwasaki (1996) also used a low dose of 6-OHDA but tested the
rats at PD 90. Future research is necessary to determine the relationship
between 6-OHDA dose and age at testing on passive avoidance learning.
The results relating to the effects of alcohol exposure on passive
avoidance learning were in partial support of our hypothesis. Specifically, when
given a high dose of alcohol (3 g/kg) both non-lesioned male and female rats as
well as sham lesioned male rats exhibited memory deficits on the third retention
day. Interestingly alcohol did not affect the performance of non-lesioned or sham
lesioned rats on the earlier test days.
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The current study demonstrated memory deficits in both sexes, while a
past investigations only saw deficits in female rats (Abel,1982; Barron & Riley,
1990). The Barron and Riley (1990) study, like the current investigation,
specifically assessed sex differences, but had a number of important
methodological differences from our study. First, was the mode of alcohol
exposure. The current study used intragastric intubation, while Barron and Riley
(1990) used artificial rearing. Second, the alcohol concentration differed. Our
study used a dose of 3 g/kg, while their dose (6.0 g/kg) was twice the amount of
the current study (Barron & Riley, 1990). It is unclear whether these
methodological differences played a role in the differing results found in the
present thesis and in the study of Barron and Riley (1990), but direct
comparisons between the two modes of exposure and level of alcohol are
warranted and could provide clarity on this issue.
Taken together, findings from the present thesis and past research
demonstrate that alcohol exposure during the neonatal period does affect
performance in male and female rats on the passive avoidance task. Further
research will be needed to determine how this alcohol effect differs by sex and
dose. Researchers may consider using doses between 3.0 to 6.0 g/kg, because
evidence suggests that during the neonatal period a higher dose of alcohol is
more effective in causing impairments in behavioral measures (Brocardo et al.,
2012; Hamilton et al., 2011).
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Conclusion
The major findings from the present thesis are fourfold: 1) 6-OHDA lesions
resulted in both a DA-deficiency and hyperactivity in male and female rats.
Moreover, psychostimulant administration increased locomotor activity instead of
attenuating this behavior. 6-OHDA lesions also resulted in an impairment in
inhibitory control and memory on the passive avoidance task. 2) Exposure to a
low dose of alcohol (0.3 g/kg) did not alter DA levels, but did cause an increase
in locomotor activity in female rats. 3) Exposure to a high dose of alcohol (3 g/kg)
did not alter DA levels or acquisition of a passive avoidance task, but did impair
memory. 4) Lastly, the combined effects of 6-OHDA lesions and alcohol did not
have an additive or synergistic effect on locomotor activity, DA depletion, or
passive avoidance performance. Taken together findings from the present thesis
and past research suggest that neonatal alcohol exposure can produce
hyperactivity and deficits in memory, but this effect differs by sex, time of
exposure, as well as a dose of alcohol. Additionally, the neurochemistry findings
suggest that DA system dysfunction may not be related to the ADHD-like
symptoms observed in alcohol-treated rats.
Because the results of previous preclinical work are inconsistent, more
research needs to be conducted in this area. Researchers may consider
investigating sex differences using various behavioral procedures and alcohol
concentrations as there is very limited data on early alcohol exposure and ADHD.
Future research on the effects of alcohol should also investigate the
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noradrenergic system as our study was not able to detect a dysfunction in the DA
system and a recent study found that atomoxetine was effective at reducing the
ADHD-like symptoms seen in alcohol treated rats (Juárez & Guerrero-Álvarez,
2015).
In conclusion, the current study provides evidence that low doses of
alcohol can have long lasting effects. This information is important as there has
been a substantial increase in alcohol consumption in women of childbearing age
as gender roles have changed (Tan et al., 2015). The results from this study may
be informative for pregnant women who consider low to moderate doses of
alcohol consumption to be acceptable or safe.
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